C
옵티팜
153710KOSDAQ의료용품 및 기타 의약 관련제품 제조업46.8 / 100
Reference Date: 2026-06-10
Financial Score11.5 / 40
News Sentiment21.3 / 25
Momentum4.0 / 20
Disclosure10.0 / 15
AI Analysis: PBR raises overvaluation concerns, ROE is below the industry average. Declined 11.2% over the past month, and news sentiment is neutral.
Company InformationBased on 2025 Annual Report
Business Overview
OptiPharm operates in multiple sectors including animal disease diagnosis, pharmaceutical development, bacteriophages, Medipig, and VLP vaccines, offering technology-driven services and products. The company differentiates itself through proprietary diagnostic systems, gene-editing technologies for transgenic animal development, and an efficient vaccine production system.
Number of Employees
79people
Average Salary
59.9M KRW
Score Calculation Basis
Detailed Financial Score
PER
—Industry Average 19.194.0Point
PBR
2.61Industry Average 1.300.0Point
2.0x industry avg (risky)
ROE
-9.48Industry Average -4.893.5Point
1.9x industry avg (good)
Debt Ratio
10.79Industry Average 6.860.5Point
1.6x industry avg (risky)
Trend 2023~20253.5 / 10 points
Revenue Growth Rate
2.5 / 3
Avg ▲13.4% (2-year basis)
Operating Profit Growth Rate
1.0 / 3
Avg ▲4.2% (2-year basis)
ROE Trend
0.0 / 4
Avg ROE -9.2% (declining, 3yr)
Detailed News Sentiment
1 totalPositive 1Neutral 0Negative 0Average Sentiment Score 85
- Positive옵티팜, 1분기 영업손실 개선…“구제역백신으로 재무 개선 가속”
옵티팜의 분기별 영업손실 개선과 매출 증가로 인해 재무 건전성이 향상되었다.
Detailed Momentum
52-week position1.0Point
Near 52w low (2%, downtrend)
Current 4,520Won52-week high 6,20052-week low 4,475
1-month return1.0Point
1m -11.20% (falling)
Volume trend2.0Point
Volume decreasing
Detailed Disclosure
3 totalPositive 0Neutral 3Negative 0
- Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-05-29
- Neutral기업설명회(IR)개최2026-05-20
- Neutral분기보고서 (2026.03)2026-05-15